Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
Details : QHRD107 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 01, 2024
Lead Product(s) : QHRD106
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess PK, Safety and Tolerability Early in Healthy Subjects
Details : QHRD106 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 29, 2024
Lead Product(s) : QHRD106
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : QHRD106
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess PK, Safety and Tolerability in Healthy Subjects
Details : QHRD106 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 24, 2024
Lead Product(s) : QHRD106
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
